RayKnowChina Research Map
Shortlist0

BeijingPeking University Health Science Center

Peking University Cancer Hospital

北京大学肿瘤医院

Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Peking University Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌2 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌82 papers led6 open trials led
  3. Hepatocellular carcinoma肝细胞癌42 papers led5 open trials led
  4. Stomach cancer胃癌223 papers led9 open trials led
  5. Osteosarcoma骨肉瘤4 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤12 papers led1 open trial led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Ewing sarcoma尤文肉瘤2 papers led
  9. Multiple myeloma多发性骨髓瘤3 papers led
  10. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎0 papers led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 2 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.08%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

5 hospitals in Beijing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic disease
Departments in papersRadiation oncology
Papers it led2
  1. Distribution of regional lymph nodes metastasis in 870 cases of nasopharyngeal carcinoma and the suggestions for individualized elective prophylactic neck irradiation with intensity-modulated radiotherapy.2024Cancer medicineFree full text
  2. GLIM Criteria-Defined Malnutrition Informs on Survival of Nasopharyngeal Carcinoma Patients Undergoing Radiotherapy.2022Nutrition and cancer
All its trials on ClinicalTrials.gov, any status7
  1. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  2. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Study sitePhase 3Start 2021-08
  3. A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT03866967Study sitePhase 2Start 2019-03
  4. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
  5. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  6. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02944708Study sitePhase 3Start 2015-10
  7. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
More papers found outside PubMed (not counted)9
  1. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  2. Impact of Radiotherapy on Radiation-Induced Brain Injury in Patients with Nasopharyngeal Carcinoma Using Nano-Magnetic Resonance Imaging2024Journal of Biomedical Nanotechnologyarticle
  3. 3D reconstruction-oriented fully automatic multi-modal tumor segmentation by dual attention-guided VNet2023The Visual Computerarticle
  4. Clinical Evaluation of AI-Assisted Virtual Contrast Enhanced MRI in Primary Gross Tumor Volume Delineation for Radiotherapy of Nasopharyngeal Carcinoma2023Lecture notes in computer scienceconference-paper
  5. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncologyconference-abstract
  6. Toripalimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma: A single-arm phase II study.2022Journal of Clinical Oncologyconference-abstract
  7. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncologyarticle
  8. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract
  9. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 82 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 2.8%.

Papers led
82
2021–2025
Trials led
30
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
11
led by another institution
Papers led per year
2021: 121220212022: 151520222023: 151520232024: 212120242025: 19192025

13 hospitals in Beijing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 17

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
    Phase
    Phase 2
    Started
    2025-03
    Registry
    NCT06869213

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  2. Recruiting
    QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07049185

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  3. Recruiting
    Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06684600

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  4. Not yet recruiting
    Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07822906

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  5. Not yet recruiting
    Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2022-12
    Registry
    NCT05386056

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  6. Enrolling by invitation
    Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07312578

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  7. Recruiting
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
    Phase
    Phase 1/Phase 2
    Started
    2026-03
    Registry
    NCT07405151

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Jinan, Xiamen, Xuzhou, Zhengzhou

  8. Recruiting
    QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07463573

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  9. Recruiting
    A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
    Phase
    Phase 2/Phase 3
    Started
    2026-06
    Registry
    NCT07554456

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  10. Recruiting
    Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07733830

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Shenyang, Taiyuan, Tianjin, Zhengzhou

  11. Recruiting
    A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07751341

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Zhengzhou

  12. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  13. Recruiting
    Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT06780111

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Hefei, Nanchang, Xiamen, Xuzhou, Zhengzhou

  14. Recruiting
    A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
    Phase
    Phase 1
    Started
    2024-07
    Registry
    NCT06465069

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  15. Recruiting
    A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
    Phase
    Phase 1/Phase 2
    Started
    2023-05
    Registry
    NCT05319730

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Hangzhou, Hefei, Shanghai, Xiamen, Xinxiang, Zhengzhou

  16. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  17. Not yet recruiting
    A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
    Phase
    Phase 2
    Started
    2026-06
    Registry
    NCT07623642

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Harbin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryNeoadjuvant & combined treatmentMolecular markers & genomics
Departments in papersMedical oncologyRadiology / nuclear medicineRadiation oncology
Papers it led82
  1. Extremely early genomic events and temporal order of esophageal squamous cell carcinogenesis: Longitudinal self-comparison of progressors and non-progressors.2025American journal of human geneticsFree full text
  2. Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers.2025BMC cancerFree full text
  3. Expression of kinetochore component NDC80 promotes esophageal squamous cell carcinoma cells proliferation and migration.2025BMC gastroenterologyFree full text
  4. Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers.2025Cancer biology & medicineFree full text
  5. Absolute Risk Prediction for Esophageal Squamous Cell Carcinoma Adaptable to Regional Disease Burden across Diverse Regions.2025Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  6. An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  7. PAF signaling axis functions as biomarker or target for esophageal squamous cell carcinoma diagnosis or treatment.2025Cancer letters
  8. Identification and characterization of Bufalin as a novel EGFR degrader.2025Cancer letters
  9. SQLE amplification accelerates esophageal squamous cell carcinoma tumorigenesis and metastasis through oncometabolite 2,3-oxidosqualene repressing Hippo pathway.2025Cancer letters
  10. An Image-Based Model for Assisting in Diagnosing Malignant Esophageal Lesions During Lugol Chromoendoscopic Examination.2025Clinical and translational gastroenterologyFree full text
  11. Persistence of Lugol-unstaining Is Associated With an Increased Risk of Progression to Malignancy in the Esophagus.2025Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  12. Prognostic impact of recurrent laryngeal nerve lymph node metastatic status in thoracic esophageal squamous cell carcinoma.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  13. Integrating tumour and lymph node radiomics features for predicting disease-free survival in locally advanced esophageal squamous cell cancer after neoadjuvant chemotherapy and complete resection.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  14. NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.2025Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  15. Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma.2025Journal of translational medicineFree full text
  16. Harnessing the FGFR2/NF2/YAP signaling-dependent necroptosis to develop an FGFR2/IL-8 dual blockade therapeutic strategy.2025Nature communicationsFree full text
  17. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial.2025Nature medicineFree full text
  18. Focal adhesion kinase/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis.2025Signal transduction and targeted therapyFree full text
  19. Treatment choices after endoscopic resection for pMM/SM1 esophageal squamous cell cancer: a retrospective study in China.2025Surgical endoscopyFree full text
  20. METTL3-mediated upregulation of FAM135B promotes EMT of esophageal squamous cell carcinoma via regulating the Wnt/β-catenin pathway.2024American journal of physiology. Cell physiology
  21. Early Contrast-Enhanced MR for Diagnosing Complete Tumor Response of Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy: A Retrospective Comparative Study.2024Annals of surgical oncology
  22. ASO Author Reflections: The Challenging Journey from cCR to pCR After Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma.2024Annals of surgical oncology
  23. Long-Term Survival and Recurrence Patterns in Locally Advanced Esophageal Squamous Cell Carcinoma Patients with Pathologic Complete Response After Neoadjuvant Chemotherapy Followed by Surgery.2024Annals of surgical oncology
  24. Exploration of lymph node recurrence patterns and delineation guidelines of radiation field in middle thoracic oesophageal carcinomas after radical surgery: a real-world study.2024BMC cancerFree full text
  25. IGH repertoire analysis at scale: deciphering the complexity of B cell infiltration and migration in esophageal squamous cell carcinoma.2024Cancer gene therapy
  26. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.2024Cancer immunology, immunotherapy : CIIFree full text
  27. Somatic CDKN2A copy number variations are associated with the prognosis of esophageal squamous cell dysplasia.2024Chinese medical journalFree full text
  28. Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase α (DGKα)/NOX4 axis.2024Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  29. LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma.2024Future oncology (London, England)Free full text
  30. Leveraging new methods for comprehensive characterization of mitochondrial DNA in esophageal squamous cell carcinoma.2024Genome medicineFree full text
  31. Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma.2024International immunopharmacology
  32. Surgical quality determines the long-term survival superiority of right over left thoracic esophagectomy for localized esophageal squamous cell carcinoma patients: a real-world multicenter study.2024International journal of surgery (London, England)Free full text
  33. Genome-Scale Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Noninvasive Esophageal Cancer Detection.2024JCO precision oncology
  34. Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.2024Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT
  35. Co-targeting TMEM16A with a novel monoclonal antibody and EGFR with Cetuximab inhibits the growth and metastasis of esophageal squamous cell carcinoma.2024Journal of translational medicineFree full text
  36. Community prevention and standardized clinical treatment jointly improve cancer outcome: Real-world evidence from an esophageal cancer patient cohort study.2024Science bulletin
  37. miR-378a-5p exerts tumor-suppressive effects on esophageal squamous cell carcinoma after neoadjuvant immunotherapy by downregulating APOC1/CEP55.2024Scientific reportsFree full text
  38. Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma.2024Signal transduction and targeted therapyFree full text
  39. AKT2S128/CCTαS315/319/323-positive cancer-associated fibroblasts (CAFs) mediate focal adhesion kinase (FAK) inhibitors resistance via secreting phosphatidylcholines (PCs).2024Signal transduction and targeted therapyFree full text
  40. Exploration of the pattern of lymph node metastasis in esophageal cancer based on membrane anatomy theory.2024Thoracic cancerFree full text
  41. Long noncoding RNA LINC01088 inhibits esophageal squamous cell carcinoma progression by targeting the NPM1-HDM2-p53 axis.2023Acta biochimica et biophysica SinicaFree full text
  42. Minimally Invasive or Open Esophagectomy for Treatment of Resectable Esophageal Squamous Cell Carcinoma? Answer From a Real-world Multicenter Study.2023Annals of surgery
  43. Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-World Data.2023Annals of surgery
  44. CT radiomics features of meso-esophageal fat in predicting overall survival of patients with locally advanced esophageal squamous cell carcinoma treated by definitive chemoradiotherapy.2023BMC cancerFree full text
  45. A CT-Based Radiomics Nomogram Model for Differentiating Primary Malignant Melanoma of the Esophagus from Esophageal Squamous Cell Carcinoma.2023BioMed research internationalFree full text
  46. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma.2023Cancer cell
  47. Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma.2023Carcinogenesis
  48. Absence of Lugol staining indicates initiation of esophageal squamous cell carcinoma: A combined genomic and epidemiologic study.2023Cell reports. MedicineFree full text
  49. Quantitative CT evaluation after two cycles of induction chemotherapy to predict prognosis of patients with locally advanced oesophageal squamous cell carcinoma before undergoing definitive chemoradiotherapy/radiotherapy.2023European radiologyFree full text
  50. High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial.2023International journal of radiation oncology, biology, physicsRCT
  51. Lugol-unstained lesions location in the esophagus affects the detection rate of malignancy: a population-based study.2023Journal of gastroenterology and hepatologyRCT
  52. Efficacy and Safety Profile of PD-1 Inhibitors Versus Chemotherapy in the Second-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2023Journal of immunotherapy (Hagerstown, Md. : 1997)
  53. Src heterodimerically activates Lyn or Fyn to serve as targets for the diagnosis and treatment of esophageal squamous cell carcinoma.2023Science China. Life sciences
  54. CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties.2023Signal transduction and targeted therapyFree full text
  55. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.2023The Lancet. Oncology
  56. Primary malignant melanoma of the esophagus: differentiation from esophageal squamous cell carcinoma and leiomyoma using dynamic contrast-enhanced CT findings.2022Abdominal radiology (New York)Free full text
  57. Response to Comment on: "Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-world Data".2022Annals of surgery
  58. Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma.2022Annals of surgical oncology
  59. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.2022BMJ (Clinical research ed.)RCTFree full text
  60. Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC).2022Cellular & molecular immunologyFree full text
  61. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.2022ESMO openRCTFree full text
  62. The m6A-induced lncRNA CASC8 promotes proliferation and chemoresistance via upregulation of hnRNPL in esophageal squamous cell carcinoma.2022International journal of biological sciencesFree full text
  63. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.2022Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  64. Characterization of somatic structural variations in 528 Chinese individuals with Esophageal squamous cell carcinoma.2022Nature communicationsFree full text
  65. Postoperative lymphatic recurrence distribution and delineation of the radiation field in lower thoracic squamous cell esophageal carcinomas: a real-world study.2022Radiation oncology (London, England)Free full text
  66. Nuclear genome-derived circular RNA circPUM1 localizes in mitochondria and regulates oxidative phosphorylation in esophageal squamous cell carcinoma.2022Signal transduction and targeted therapyFree full text
  67. Absence of NOTCH1 mutation and presence of CDKN2A deletion predict progression of esophageal lesions.2022The Journal of pathology
  68. Commentary: Endoscopic treatment is the key for superficial esophageal squamous cell neoplasia.2022The Journal of thoracic and cardiovascular surgery
  69. Association between polymorphisms of ABCB1 and prognosis in esophageal squamous cell carcinoma patients treated with taxane.2022The journal of gene medicine
  70. The metabolic genomic atlas reveals potential drivers and clinically relevant insights into the etiology of esophageal squamous cell carcinoma.2022TheranosticsFree full text
  71. MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma.2021Cancer communications (London, England)Free full text
  72. BAALC-AS1/G3BP2/c-Myc feedback loop promotes cell proliferation in esophageal squamous cell carcinoma.2021Cancer communications (London, England)Free full text
  73. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.2021Cancer medicineFree full text
  74. NOX5 mediates the crosstalk between tumor cells and cancer-associated fibroblasts via regulating cytokine network.2021Clinical and translational medicineFree full text
  75. Tumor-associated autoantibodies in ESCC screening: Detecting prevalent early-stage malignancy or predicting future cancer risk?2021EBioMedicineFree full text
  76. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.2021Future oncology (London, England)RCT
  77. Polymorphism of FGD4 and myelosuppression in patients with esophageal squamous cell carcinoma.2021Future oncology (London, England)
  78. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.2021JAMA surgeryRCTFree full text
  79. Genomic and epigenomic evolution of acquired resistance to combination therapy in esophageal squamous cell carcinoma.2021JCI insightFree full text
  80. Predicting Lymph Node Metastasis Using Computed Tomography Radiomics Analysis in Patients With Resectable Esophageal Squamous Cell Carcinoma.2021Journal of computer assisted tomography
  81. Feed-forward activation of STAT3 signaling limits the efficacy of c-Met inhibitors in esophageal squamous cell carcinoma (ESCC) treatment.2021Molecular carcinogenesis
  82. MXD1 is a Potential Prognostic Biomarker and Correlated With Specific Molecular Change and Tumor Microenvironment Feature in Esophageal Squamous Cell Carcinoma.2021Technology in cancer research & treatmentFree full text
All its trials on ClinicalTrials.gov, any status59
  1. Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and SurgeryNot yet recruitingNCT07822906Lead sponsorStart 2026-10
  2. A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous CarcinomaRecruitingNCT06869213Lead sponsorPhase 2Start 2025-03
  3. QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07049185Lead sponsorPhase 2Start 2025-09
  4. Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal CancerActive, not recruitingNCT07745322Lead sponsorStart 2026-05
  5. HAIC Combined Sintilimab for Liver Metastasis From Esophageal Squamous Cell CarcinomaCompletedNCT06184841Lead sponsorPhase 1Start 2020-06
  6. Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal LesionsStatus unknownNCT04170257Lead sponsorN/AStart 2019-10
  7. Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal CarcinomaCompletedNCT02850991Lead sponsorN/AStart 2016-04
  8. Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy(nCT) in the Treatment of Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT07312578Lead (inferred)Phase 2Start 2025-11
  9. Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06684600Lead (inferred)Phase 2Start 2024-11
  10. Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell CarcinomaNot yet recruitingNCT05386056Lead (inferred)Phase 2Start 2022-12
  11. Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of IPM514 in Patients with Esophageal Squamous Cell CarcinomaStatus unknownNCT06690476Lead (inferred)Early phase 1Start 2024-10
  12. Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal CancerStatus unknownNCT05866510Lead (inferred)Phase 2Start 2023-05
  13. To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCCStatus unknownNCT05818982Lead (inferred)Phase 2Start 2023-02
  14. Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell CarcinomaTerminatedNCT04804696Lead (inferred)Phase 2Start 2021-02
  15. JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyStatus unknownNCT05164848Lead (inferred)Phase 1Start 2021-12
  16. The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaStatus unknownNCT04937673Lead (inferred)Phase 2Start 2021-07
  17. Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationStatus unknownNCT04880811Lead (inferred)Phase 2Start 2021-07
  18. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsStatus unknownNCT04584008Lead (inferred)N/AStart 2020-09
  19. Metformin in Combined With Cisplatin Plus Paclitaxel With Advanced Esophageal Squamous Cell Carcinoma (ECMTPneo)Status unknownNCT03833466Lead (inferred)Phase 2Start 2019-02
  20. Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01)Status unknownNCT03940976Lead (inferred)Phase 2Start 2019-04
  21. Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive SystemStatus unknownNCT03185988Lead (inferred)Phase 2Start 2017-07
  22. Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell CarcinomaTerminatedNCT03251417Lead (inferred)Phase 2Start 2017-09
  23. Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03126708Lead (inferred)Phase 2Start 2017-04
  24. Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell CarcinomaCompletedNCT02645864Lead (inferred)Phase 1Start 2016-01
  25. Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric CancerStatus unknownNCT02375997Lead (inferred)Phase 3Start 2014-10
  26. Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell CarcinomaWithdrawnNCT02272699Lead (inferred)Phase 2/Phase 3Start 2014-11
  27. Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.Status unknownNCT01993784Lead (inferred)Phase 1/Phase 2Start 2013-08
  28. Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell CancerStatus unknownNCT02016287Lead (inferred)Phase 2Start 2013-12
  29. Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell CancerStatus unknownNCT02016274Lead (inferred)Phase 2Start 2013-12
  30. Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)Active, not recruitingNCT01688908Lead (inferred)N/AStart 2012-01
  31. Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Study sitePhase 2Start 2026-07
  32. QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell CarcinomaRecruitingNCT07463573Study sitePhase 3Start 2026-04
  33. A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.Not yet recruitingNCT07623642Study sitePhase 2Start 2026-06
  34. A Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07751341Study sitePhase 2Start 2026-09
  35. A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)RecruitingNCT07554456Study sitePhase 2/Phase 3Start 2026-06
  36. A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)RecruitingNCT07405151Study sitePhase 1/Phase 2Start 2026-03
  37. Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingNCT06780111Study sitePhase 1/Phase 2Start 2025-07
  38. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  39. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsRecruitingNCT06465069Study sitePhase 1Start 2024-07
  40. A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Study sitePhase 1/Phase 2Start 2023-05
  41. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  42. A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)Active, not recruitingNCT06304974Study sitePhase 3Start 2024-03
  43. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  44. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  45. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  46. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Study sitePhase 3Start 2021-07
  47. JAB-3068 Activity in Adult Patients With Advanced Solid TumorsCompletedNCT04721223Study sitePhase 1/Phase 2Start 2021-04
  48. A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaCompletedNCT04121286Study sitePhase 1Start 2020-07
  49. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  50. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  51. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  52. Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )CompletedNCT03748134Study sitePhase 3Start 2018-12
  53. A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in ChinaCompletedNCT03565003Study sitePhase 1/Phase 2Start 2018-11
  54. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyCompletedNCT03933449Study sitePhase 3Start 2016-12
  55. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  56. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Study sitePhase 3Start 2015-03
  57. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell CarcinomaCompletedNCT02395705Study sitePhase 3Start 2015-06
  58. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
  59. A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous CarcinomaStatus unknownNCT00642239Study sitePhase 4Start 2008-04
More papers found outside PubMed (not counted)62
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. 474TiP IDeate-Esophageal01: A phase III, randomized, open-label study of ifinatamab deruxtecan (I-DXd) in patients (pts) with pretreated advanced/metastatic esophageal squamous cell carcinoma (ESCC)2025Annals of Oncologyarticle
  3. 67eP ACR246, a novel 5T4 antibody-drug conjugate, showed promising anticancer efficacy in esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  4. 963P SC-101, a Nectin-4-targeting peptide-drug conjugate (PDC), in patients (pts) with advanced or metastatic solid tumors: Results from dose escalation study2025Annals of Oncologyarticle
  5. A multi-epitope mRNA vaccine for effective immunotherapy in esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyarticle
  6. Impact of tislelizumab + chemotherapy versus placebo + chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): 2025Journal of Clinical Oncologyconference-abstract
  7. KEYMAKER-U06 substudy 06E: A phase 1/2 open-label, umbrella platform study of ifinatamab deruxtecan in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma (ESCC2025Journal of Clinical Oncologyarticle
  8. LBA79 Lenvatinib plus pembrolizumab and chemotherapy vs pembrolizumab and chemotherapy in untreated metastatic esophageal squamous cell carcinoma: The randomized phase III LEAP-014 study2025Annals of Oncologyconference-abstract
  9. PT2.10.03 Safety, Tolerability and Preliminary Efficacy of Anti-PD-L1 ADC HLX43 in Advanced/Metastatic Solid Tumors: A Phase I Study2025Journal of Thoracic Oncologyarticle
  10. Perioperative adebrelimab combined with chemotherapy for locally advanced resectable esophageal squamous cell carcinoma: A single-arm, open-label, multicenter study.2025Journal of Clinical Oncologyconference-abstract
  11. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncologyconference-abstract
  12. 1426P BL-B01D1, an EGFR x her3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)2024Annals of Oncologyarticle
  13. 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies2024Annals of Oncologyarticle
  14. 265TiP Phase I/II open-label, umbrella platform designed study of investigational agents with or without pembrolizumab and/or chemotherapy in patients with advanced esophageal cancer previously treated with a PD-(L)1 inhibitor: KEYMAKER-U062024Annals of Oncologyarticle
  15. Abstract CT209: Camrelizumab plus chemotherapy as neoadjuvant treatment for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): A single-center, randomized, phase II trial2024Cancer Researchconference-abstract
  16. Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncologyconference-abstract
  17. Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.2024Journal of Clinical Oncologyconference-abstract
  18. Neoadjuvant Immunotherapy combined with Chemoradiotherapy VS. Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma(cStageII-III): Study Protocol For A Multi-center Prospective Randomized Clinical Trial2024Research Squarepreprint
  19. Octadecyl Gallate and Lipid‐Modified MnSe2 Nanoparticles Enhance Radiosensitivity in Esophageal Squamous Cell Carcinoma and Promote Radioprotection in Normal Tissues (Adv. Mater. 23/2024)2024Advanced Materialsarticle
  20. Real-world data of anlotinib for gastrointestinal tumors with liver metastases in China.2024Journal of Clinical Oncologyconference-abstract
  21. SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncologyconference-abstract
  22. Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.2024Journal of Clinical Oncologyconference-abstract
  23. 1534P First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (mESCC): Safety run-in results from the phase III LEAP-014 study2023Annals of Oncologyarticle
  24. 189P Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)2023Annals of Oncologyarticle
  25. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Researchconference-abstract
  26. Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis2023Cancer Researchconference-abstract
  27. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  28. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  29. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  30. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  31. Data from Long Noncoding RNA VESTAR Regulates Lymphangiogenesis and Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma by Enhancing VEGFC mRNA Stability2023Venue not listedother
  32. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncologyconference-abstract
  33. MO19-4 Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma2023Annals of Oncologyarticle
  34. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncologyarticle
  35. 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup2022Annals of Oncologyarticle
  36. 80P RATIONALE-302: Tislelizumab vs chemotherapy as second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC): Impact on health-related quality of life (HRQoL) in Asian patients2022Annals of Oncologyarticle
  37. ASO Visual Abstract: Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma2022Annals of Surgical Oncologyarticle
  38. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  39. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  40. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  41. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  42. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset
  43. First-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress.2022Journal of Clinical Oncologyconference-abstract
  44. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.2022Journal of Clinical Oncologyconference-abstract
  45. LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract
  46. Nimotuzumab plus concurrent chemo-radiotherapy versus chemo-radiotherapy in unresectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis from a prospective, randomized-controlled, double-blinded, multicenter, an2022Journal of Clinical Oncologyconference-abstract
  47. P-298 Open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma: LEAP-014 trial in progress2022Annals of Oncologyconference-abstract
  48. Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncologyconference-abstract
  49. Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.2022Journal of Clinical Oncologyconference-abstract
  50. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).2022Journal of Clinical Oncologyconference-abstract
  51. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).2022Journal of Clinical Oncologyconference-abstract
  52. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  53. 155P Surufatinib plus toripalimab for second-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, esophageal squamous cell carcinoma (ESCC) and neuroendocrine carcinoma (NEC): A multicenter, single-arm pha2021Annals of Oncologyarticle
  54. Comparison of Two Major Staging Systems in Predicting Survival and Recommendation of Postoperative Radiotherapy Based on the 11th Japanese Classification for Esophageal Carcinoma After Curative Resection2021International Journal of Radiation Oncology*Biology*Physicsarticle
  55. Determining an Evidence-Based Surveillance Target and Respective Intervals for Esophageal Squamous Cell Carcinoma Following Screening: A Population-Based Cohort Study in China2021SSRN Electronic Journalpreprint
  56. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).2021Journal of Clinical Oncologyconference-abstract
  57. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.2021Journal of Clinical Oncologyconference-abstract
  58. Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.2021Journal of Clinical Oncologyconference-abstract
  59. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncologyconference-abstract
  60. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset
  61. O-15 Randomized, phase 3 study of second-line tislelizumab vs chemotherapy in advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302) in the overall population and Europe/North America subgroup2021Annals of Oncologyconference-abstract
  62. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 42 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
42
2021–2025
Trials led
15
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 7720212022: 131320222023: 8820232024: 5520242025: 772025

17 hospitals in Beijing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase I Study of OriC902 in Treatment of Advanced HCC
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06891742

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing

  2. Recruiting
    Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06360042

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  3. Recruiting
    Mts105 for Advanced Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06689540

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  4. Recruiting
    Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
    Phase
    Phase 2
    Started
    2023-06
    Registry
    NCT05917431

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  5. Not yet recruiting
    SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07882056

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  6. Recruiting
    Study of GV20-0251 in Participants With Solid Tumor Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07070518

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  7. Recruiting
    A Study of DEG6498 in Participants With Solid Tumors
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07244835

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou

  8. Recruiting
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07594964

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  9. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  10. Recruiting
    Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
    Phase
    Phase 1/Phase 2
    Started
    2022-12
    Registry
    NCT05652920

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Hangzhou, Shanghai

  11. Not yet recruiting
    A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07583316

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Radiation oncologyMedical oncology
Papers it led42
  1. Negative 68Ga-FAPI-04 Uptake on PET/CT in HNF-1α-mutated Hepatocellular Adenoma: A Distinctive Feature for Differentiating From Hepatocellular Carcinoma.2026Clinical nuclear medicine
  2. Radiotherapy combined with anti-PD-1 immunotherapy promotes ferroptosis-driven control of hepatocellular carcinoma.2026Genes and immunityFree full text
  3. Effect of AFP and PIVKA-II secretion status on prognosis of advanced hepatocellular carcinoma patients receiving TACE combined with systemic therapy.2025BMC cancerFree full text
  4. Identification of Key Genes and Pathways in Lenvatinib-resistant Hepatocellular Carcinoma using Bioinformatic Analysis and Experimental Validation.2025Current medicinal chemistry
  5. SIRT4 Controls Acetyl-CoA Synthesis to Promote Stemness and Invasiveness of Hepatocellular Carcinoma through Deacetylating MCCC2.2025International journal of biological sciencesFree full text
  6. Long non-coding RNA LINC01532 sustains redox homeostasis and accelerates lenvatinib resistance in hepatocellular carcinoma.2025Journal of advanced researchFree full text
  7. The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial.2025Nature communicationsFree full text
  8. PFDN6L Gene Predicts Good Prognosis Associated with Its Inhibition of the Stem-Ness Properties in Hepatocellular Carcinoma.2025Oncology researchFree full text
  9. Targeting NETO2 suppresses cell proliferation, invasion, and migration and inactivates the STAT3/C-MYC pathway in hepatocellular carcinoma.2025World journal of surgical oncologyFree full text
  10. Toripalimab Plus Bevacizumab as First-line Treatment for Advanced Hepatocellular Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Trial.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  11. GSTA1/CTNNB1 axis facilitates sorafenib resistance via suppressing ferroptosis in hepatocellular carcinoma.2024Pharmacological research
  12. A novel nomogram for prediction of intrahepatic recurrence-free survival in patients with HCC followed by radiofrequency ablation.2024The British journal of radiologyFree full text
  13. Multimode Ultrasound Model for Predicting the Early Treatment Response of Anti-VEGF Agents Plus Anti-PD-1 Antibody in Patients with Unresectable Hepatocellular Carcinoma.2024Ultrasound in medicine & biology
  14. Evaluation of the Time Difference Method in Identifying Hepatocellular Carcinoma in Current CEUS LR-M Category Nodules.2024Ultrasound in medicine & biology
  15. Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.2023Cell reports. MedicineFree full text
  16. Effect of vessels that encapsulate tumor clusters (VETC) on the prognosis of different stages of hepatocellular carcinoma after hepatectomy.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  17. An evaluation of 20-year survival of radiofrequency ablation for hepatocellular carcinoma as first-line treatment.2023European journal of radiology
  18. Evaluation of the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation for hepatocellular carcinoma and liver metastases adjacent to the gallbladder.2023International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  19. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.2023Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  20. Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress.2023Journal of experimental & clinical cancer research : CRFree full text
  21. Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: A propensity score-matched analysis based on phase II study.2023Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  22. Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.2023The Lancet. Oncology
  23. Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma.2022BMC cancerFree full text
  24. Liver tumor-initiating cells initiate the formation of a stiff cancer stem cell microenvironment niche by secreting LOX.2022Carcinogenesis
  25. A nomogram based on a three pyroptosis gene model and clinical parameters for predicting prognosis of hepatocellular carcinoma.2022Gene
  26. Diagnostic value of color parametric imaging and contrast-enhanced ultrasound in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma.2022Journal of clinical ultrasound : JCU
  27. PPP1R26 drives hepatocellular carcinoma progression by controlling glycolysis and epithelial-mesenchymal transition.2022Journal of experimental & clinical cancer research : CRFree full text
  28. Prognostic significance of albumin-bilirubin score in patients with unresectable hepatocellular carcinoma undergoing combined immunotherapy and radiotherapy.2022Journal of medical imaging and radiation oncology
  29. Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial.2022Journal of nuclear medicine : official publication, Society of Nuclear MedicineFree full text
  30. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.2022Molecular cancerFree full text
  31. Long non‑coding RNA LINC00238 suppresses the malignant phenotype of liver cancer by sponging miR‑522.2022Molecular medicine reportsFree full text
  32. Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  33. A Multicenter Randomized Controlled Study of Contrast-enhanced US versus US-guided Biopsy of Focal Liver Lesions.2022RadiologyRCT
  34. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial.2022RadiologyRCT
  35. Computer-Aided Color Parameter Imaging of Contrast-Enhanced Ultrasound Evaluates Hepatocellular Carcinoma Hemodynamic Features and Predicts Radiofrequency Ablation Outcome.2022Ultrasound in medicine & biology
  36. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.2021BioMed research internationalFree full text
  37. The effect of propofol on the proliferation and apoptosis of hepatocellular carcinoma cells through TGF-Β1/Smad2 signaling pathway.2021BioengineeredFree full text
  38. Inhibiting CBX4 efficiently protects hepatocellular carcinoma cells against sorafenib resistance.2021British journal of cancerFree full text
  39. Epidemiology of Alcohol-Associated Liver Disease.2021Clinics in liver diseaseFree full text
  40. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.2021Immunotherapy
  41. γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.2021Journal of vascular and interventional radiology : JVIR
  42. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC.2021Radiology
Chinese-language papers (not in the count)1
  1. [Atezolizumab therapy in Chinese patients with locally advanced or metastatic solid tumors: An open-label, phase Ⅰ study].2022Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
All its trials on ClinicalTrials.gov, any status50
  1. SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular CarcinomaNot yet recruitingNCT07882056Lead sponsorPhase 2Start 2026-10
  2. Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Lead sponsorPhase 2Start 2024-01
  3. Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCCRecruitingNCT05917431Lead sponsorPhase 2Start 2023-06
  4. The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular CarcinomaStatus unknownNCT05862181Lead sponsorStart 2023-01
  5. The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04542837Lead sponsorPhase 2Start 2020-09
  6. Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After ResectionStatus unknownNCT02767375Lead sponsorPhase 2/Phase 3Start 2015-02
  7. A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma PatientsStatus unknownNCT02727309Lead sponsorPhase 1/Phase 2Start 2015-10
  8. The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular CarcinomaStatus unknownNCT03143140Lead sponsorN/AStart 2014-05
  9. Phase I Study of OriC902 in Treatment of Advanced HCCRecruitingNCT06891742Lead (inferred)Phase 1Start 2025-02
  10. Mts105 for Advanced Hepatocellular CarcinomaRecruitingNCT06689540Lead (inferred)Phase 1Start 2024-11
  11. HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary InvasionActive, not recruitingNCT07466225Lead (inferred)Start 2026-05
  12. Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.TerminatedNCT05171166Lead (inferred)Phase 2/Phase 3Start 2021-12
  13. Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular CarcinomaStatus unknownNCT04042805Lead (inferred)Phase 2Start 2019-08
  14. Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor ThrombosisCompletedNCT03009461Lead (inferred)Phase 2Start 2017-06
  15. A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCCStatus unknownNCT01997957Lead (inferred)Phase 4Start 2013-10
  16. A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid TumorsNot yet recruitingNCT07583316Study sitePhase 1Start 2026-05
  17. A Study of DEG6498 in Participants With Solid TumorsRecruitingNCT07244835Study sitePhase 1Start 2025-11
  18. Study of GV20-0251 in Participants With Solid Tumor MalignanciesRecruitingNCT07070518Study sitePhase 1/Phase 2Start 2025-07
  19. To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsRecruitingNCT07594964Study sitePhase 1Start 2025-08
  20. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  21. Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCCRecruitingNCT05652920Study sitePhase 1/Phase 2Start 2022-12
  22. A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCCWithdrawnNCT05212922Study sitePhase 2Start 2023-06
  23. A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Active, not recruitingNCT05904886Study sitePhase 3Start 2023-09
  24. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Study sitePhase 2Start 2022-12
  25. A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCCCompletedNCT04948697Study sitePhase 2Start 2021-08
  26. A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/BevActive, not recruitingNCT04649489Study sitePhase 3Start 2021-04
  27. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Study sitePhase 2Start 2021-03
  28. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  29. A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)CompletedNCT04605796Study sitePhase 2Start 2020-04
  30. Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCCCompletedNCT04723004Study sitePhase 3Start 2020-10
  31. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid TumorActive, not recruitingNCT04008797Study sitePhase 1/Phase 2Start 2019-07
  32. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  33. A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Study sitePhase 3Start 2019-12
  34. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  35. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  36. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  37. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  38. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  39. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Study sitePhase 3Start 2018-03
  40. Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)CompletedNCT03062358Study sitePhase 3Start 2017-04
  41. Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal TumorsStatus unknownNCT03507998Study sitePhase 1Start 2017-06
  42. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12
  43. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  44. Hepatocellular Carcinoma Registry in Asia: The INSIGHT RegistryCompletedNCT03233360Study siteStart 2017-04
  45. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  46. STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular CarcinomaCompletedNCT03113955Study siteN/AStart 2017-10
  47. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06
  48. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular CarcinomaCompletedNCT01988493Study sitePhase 1/Phase 2Start 2014-01
  49. Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT00617981Study sitePhase 3Start 2008-05
  50. T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma PatientsTerminatedNCT00057382Study sitePhase 2/Phase 3Start 2003-03

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 223 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 2.3%.

Papers led
223
2021–2025
Trials led
53
any status, ClinicalTrials.gov
Open trials led
9
recruiting or about to
Open trials as a site
33
led by another institution
Papers led per year
2021: 535320212022: 393920222023: 404020232024: 393920242025: 44442025

15 hospitals in Beijing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 42

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    ctDNA-MRD Monitoring After Resection in Gastric Cancer
    Phase
    Not given
    Started
    2025-04
    Registry
    NCT06893133

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  2. Recruiting
    Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07127822

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Harbin, Qingdao, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  3. Recruiting
    NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06134960

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  4. Recruiting
    Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
    Phase
    N/A
    Started
    2024-06
    Registry
    NCT06306755

    Age 50 years to 69 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  5. Recruiting
    Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
    Phase
    N/A
    Started
    2024-08
    Registry
    NCT06429891

    Age 18 years to 70 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  6. Recruiting
    Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
    Phase
    Phase 2
    Started
    2024-09
    Registry
    NCT06580574

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  7. Recruiting
    Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
    Phase
    Phase 2
    Started
    2023-09
    Registry
    NCT06023758

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  8. Recruiting
    Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
    Phase
    N/A
    Started
    2019-09
    Registry
    NCT04047953

    Age 18 years to 75 years (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  9. Not yet recruiting
    Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07656740

    Age not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  10. Recruiting
    A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
    Phase
    Phase 2/Phase 3
    Started
    2026-03
    Registry
    NCT07221149

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Nanning, Shanghai

  11. Recruiting
    A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-01
    Registry
    NCT07315750

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  12. Recruiting
    A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2026-01
    Registry
    NCT07354711

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  13. Recruiting
    LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07362186

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  14. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  15. Recruiting
    A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07518147

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  16. Recruiting
    Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07522151

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  17. Recruiting
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07700979

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai

  18. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  19. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  20. Recruiting
    A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06760819

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Shanghai

  21. Recruiting
    BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06773312

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  22. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  23. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  24. Recruiting
    A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-08
    Registry
    NCT07023315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Harbin, Shanghai, Shijiazhuang

  25. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  26. Recruiting
    An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2025-12
    Registry
    NCT07371663

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Hangzhou, Zhengzhou

  27. Recruiting
    To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07594964

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

  28. Recruiting
    DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
    Phase
    Phase 2/Phase 3
    Started
    2024-02
    Registry
    NCT06221748

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Harbin, Jinan, Kunming, Qingdao, Shanghai, Wuhan, Xiamen, Xuzhou, Zhengzhou

  29. Recruiting
    Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06469944

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Nanchang, Shanghai, Urumqi, Xiamen, Zhengzhou

  30. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  31. Recruiting
    A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07547787

    Age not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  32. Recruiting
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05722275

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Kunming, Taiyuan, Zhengzhou

  33. Recruiting
    A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06008054

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  34. Recruiting
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    Phase
    Not given
    Started
    2023-09
    Registry
    NCT06035250

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Kunming, Nanning, Qingdao, Shanghai, Shenyang, Suzhou, Tianjin, Zhengzhou

  35. Recruiting
    Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 2
    Started
    2023-11
    Registry
    NCT06155383

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Jinan, Kunming, Xiamen, Zhengzhou

  36. Recruiting
    M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
    Phase
    Phase 3
    Started
    2023-12
    Registry
    NCT06177041

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  37. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  38. Recruiting
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2022-10
    Registry
    NCT05208762

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai

  39. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
    Phase
    Phase 1
    Started
    2022-02
    Registry
    NCT05262491

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin

  40. Recruiting
    Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2021-06
    Registry
    NCT04900818

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Harbin, Hefei, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou

  41. Not yet recruiting
    A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06944496

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing

  42. Not yet recruiting
    A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
    Phase
    Phase 1
    Started
    2024-11
    Registry
    NCT06614751

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsChemotherapy & combined treatment
Departments in papersMedical oncologyRadiology / nuclear medicinePathology / laboratory medicineRadiation oncology
Papers it led223
  1. Discordance in tumour response assessment for gastric cancer after neoadjuvant chemotherapy using different methods.2026Abdominal radiology (New York)
  2. Characterization of Microplastics in Human Gastric Cancer and Control Tissues and Analysis of Associated Genetic Features.2026Advanced healthcare materialsFree full text
  3. TOPK Inhibition Promotes Anti-Tumor Immunity Via eIF4F Complex Mediated STAT1 Translation in Gastric Cancer.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Impact of concomitant medications on efficacy of CLDN18.2-specific CAR-T cell therapy in advanced gastric cancer.2026British journal of cancer
  5. Predicting 177Lu-DOTATATE therapy response through immune microenvironment parameters in gastroenteropancreatic neuroendocrine tumors (GEP-NETs).2026European journal of nuclear medicine and molecular imaging
  6. Postoperative infectious complications in gastric and colorectal cancer patients: A multicenter prospective cohort study from China.2026Surgery
  7. Comparison of postoperative reflux esophagitis in different digestive tract reconstruction methods after proximal gastrectomy for proximal gastric cancer patients: a network meta-analysis and systematic review.2026Updates in surgery
  8. Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases.2026Virchows Archiv : an international journal of pathology
  9. A CLDN18.2-Targeted Nanoplatform Manipulates Magnetic Hyperthermia Spatiotemporally for Synergistic Immunotherapy in Gastric Cancer.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  10. Utilizing Combined Circulating Tumor DNA and Tumor Markers to Evaluate Neoadjuvant Therapy Response and Predict Recurrence in Patients with Locally Advanced Gastric Cancer.2025Annals of surgical oncology
  11. The value of translational therapy in the treatment of advanced hepatoid adenocarcinoma of stomach.2025BMC cancerFree full text
  12. Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers.2025BMC cancerFree full text
  13. Clinicopathologic characteristics and prognostic factors of pure gastric neuroendocrine carcinoma patients undergoing radical surgery.2025BMC cancerFree full text
  14. Comprehensive evaluation of tumor response better evaluates the efficacy of neoadjuvant chemotherapy and predicts the prognosis in gastric cancer - a post hoc analysis of a single-center randomized controlled trial.2025BMC cancerRCTFree full text
  15. Immune microenvironment spatial landscapes of tertiary lymphoid structures in gastric cancer.2025BMC medicineFree full text
  16. Comparison of the safety of esophagojejunal overlap and π-shaped anastomosis in totally laparoscopic total gastrectomy.2025BMC surgeryFree full text
  17. Effect of risk-based screening for upper gastrointestinal cancers: a multi-center real-world study.2025British journal of cancerFree full text
  18. Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer.2025British journal of cancerFree full text
  19. Proteomic profiling and scRNA sequencing identify signatures associated with Helicobacter pylori infection and risk of developing gastric cancer.2025Cancer biology & medicineFree full text
  20. Plasma L-aspartic acid predicts the risk of gastric cancer and modifies the primary prevention effect: a multistage metabolomic profiling and Mendelian randomization study.2025Cancer biology & medicineFree full text
  21. Advances and challenges in gastric cancer testing: the role of biomarkers.2025Cancer biology & medicineFree full text
  22. Harnessing exosomes: From tumor immune escape to therapeutic innovation in gastric cancer immunotherapy.2025Cancer letters
  23. Hepatoid adenocarcinoma of the stomach and non-hepatoid alpha-fetoprotein-producing gastric cancer exhibit a high degree of molecular similarity.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  24. Feasibility and long-term survival of proximal gastrectomy after neoadjuvant therapy for locally advanced proximal gastric cancer: A propensity-score-matched analysis.2025Chinese medical journalFree full text
  25. Ginkgolide B Inhibits EMT and Promotes Pyroptosis in Gastric Cancer via AKT/mTOR Pathway.2025Drug design, development and therapyFree full text
  26. Integrating genetics and transcriptomics to decipher susceptibility genes for risk stratification of gastric cancer and effect modification of Helicobacter pylori treatment.2025EBioMedicineFree full text
  27. Computed tomography features of gastric cancer with deficient mismatch repair: Radiologic-pathologic correlation.2025European journal of radiology
  28. Identifying potential beneficiaries of neoadjuvant therapy in borrmann type III and IV gastric cancer: A treatment heterogeneity analysis using causal survival forests.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  29. CT radiomics-based intratumoral and intertumoral heterogeneity indicators for prognosis prediction in gastric cancer patients receiving neoadjuvant chemotherapy.2025European radiology
  30. Multi-omic profiling identifies KRT1 as a predictor of immune infiltration and prognosis in gastroesophageal junction cancer.2025Functional & integrative genomics
  31. Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  32. Host Genetic Variants Associated With Helicobacter pylori Infection: A Meta-Analysis Combined With Functional Annotation.2025Helicobacter
  33. Enhanced HER2 status detection in breast and gastric cancers using surrogate DNA methylation markers.2025IUBMB life
  34. Integrative metabolomics and microbiomics analysis reveals distinctive microbiota-metabolites interactions in gastric carcinogenesis.2025International journal of cancer
  35. First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer: The GEMSTONE-303 Randomized Clinical Trial.2025JAMARCTFree full text
  36. Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer: A Randomized Clinical Trial.2025JAMA oncologyRCTFree full text
  37. Impact of Psychological Factors on Survival in Metastatic Esophagogastric Cancer: Secondary Analysis of a Randomized Controlled Trial.2025JCO oncology practiceRCT
  38. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis.2025Journal of hematology & oncologyFree full text
  39. Short-term outcomes of robotic versus laparoscopic gastrectomy for proximal gastric cancer: a systematic review and meta-analysis of propensity score-matched or baseline-balanced retrospective studies.2025Journal of robotic surgery
  40. Laparoscopic vs robot-assisted gastrectomy in gastric cancer patients with prior abdominal surgery: a propensity-matched analysis.2025Journal of robotic surgery
  41. Serum miR-30c serves as potential biomarkers for the diagnosis and prognosis of gastric cancer.2025Journal of toxicology and environmental health. Part A
  42. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.2025Lancet (London, England)RCT
  43. Advances in the study of the role of gastric microbiota in the progression of gastric cancer.2025Microbial pathogenesis
  44. The accumulation of myeloid-derived suppressor cells participates in abdominal infection-induced tumor progression through the PD-L1/PD-1 axis.2025Molecular oncologyFree full text
  45. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial.2025Nature medicineFree full text
  46. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.2025Nature medicineRCT
  47. Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value.2025Scientific reportsFree full text
  48. PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial.2025Signal transduction and targeted therapyFree full text
  49. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final re2025The Lancet. OncologyRCT
  50. Noninvasive in vivo tracking of SPIONs-labeled CLDN18.2-targeted CAR-T cells in gastric cancer via magnetic particle imaging.2025Translational research : the journal of laboratory and clinical medicine
  51. Diagnostic accuracy of stereomicroscopy assessment of invasion depth in ex vivo specimens of early gastric cancer.2025World journal of gastroenterologyFree full text
  52. Lymph node metastatic patterns of gastric carcinoma with a combination of adenocarcinoma and neuroendocrine carcinoma components.2025World journal of gastroenterologyFree full text
  53. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.2024Advances in therapyFree full text
  54. Pre- and Post-treatment Double-Sequential-Point Dynamic Radiomic Model in the Response Prediction of Gastric Cancer to Neoadjuvant Chemotherapy: 3-Year Survival Analysis.2024Annals of surgical oncology
  55. A modified esophagogastric reconstruction method after laparoscopic proximal gastrectomy: A technical note with video vignette.2024Asian journal of surgery
  56. Long-term outcomes of laparoscopic versus open total gastrectomy in patients with advanced gastric cancer after neoadjuvant chemotherapy: a retrospective cohort study.2024BMC cancerFree full text
  57. Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer.2024British journal of cancerFree full text
  58. Advances in MET tyrosine kinase inhibitors in gastric cancer.2024Cancer biology & medicineFree full text
  59. Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers.2024Cancer immunology, immunotherapy : CIIFree full text
  60. Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.2024Cancer immunology, immunotherapy : CIIFree full text
  61. Phase I study of BC001, a novel fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, in advanced solid tumors.2024Cancer medicineFree full text
  62. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression.2024Cell communication and signaling : CCSFree full text
  63. Exploration of molecular markers related to chemotherapy efficacy of hepatoid adenocarcinoma of the stomach.2024Cellular oncology (Dordrecht, Netherlands)Free full text
  64. Development and external validation of a quantitative diagnostic model for malignant gastric lesions in clinical opportunistic screening: A multicenter real-world study.2024Chinese medical journalFree full text
  65. Single-cell characterization of differentiation trajectories and drug resistance features in gastric cancer with peritoneal metastasis.2024Clinical and translational medicineFree full text
  66. ABCC2 induces metabolic vulnerability and cellular ferroptosis via enhanced glutathione efflux in gastric cancer.2024Clinical and translational medicineFree full text
  67. Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification.2024Clinical and translational scienceFree full text
  68. [177Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models.2024European journal of nuclear medicine and molecular imaging
  69. MiRNA29a-3p negatively regulates ISL1-Integrin β1 axis to suppress gastric cancer progression.2024Experimental cell research
  70. CDKN2A somatic copy number amplification in normal tissues surrounding gastric carcinoma reduces cancer metastasis risk in droplet digital PCR analysis.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  71. Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  72. Intratumoral microbiome is associated with gastric cancer prognosis and therapy efficacy.2024Gut microbesFree full text
  73. Tracking circulating PD-L1-positive cells to monitor the outcome of patients with gastric cancer receiving anti-HER2 plus anti-PD-1 therapy.2024Human cellFree full text
  74. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.2024Human pathology
  75. The tumor immune microenvironment remodeling and response to HER2-targeted therapy in HER2-positive advanced gastric cancer.2024IUBMB life
  76. A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening.2024International journal of cancer
  77. Multiple approaches revealed MGc80-3 as a somatic hybrid with HeLa cells rather than a gastric cancer cell line.2024International journal of cancer
  78. Helicobacter pylori Treatment and Gastric Cancer Risk Among Individuals With High Genetic Risk for Gastric Cancer.2024JAMA network openFree full text
  79. Dynamic change in the peritoneal cancer index based on CT after chemotherapy in the overall survival prediction of gastric cancer patients with peritoneal metastasis.2024Journal of cancer research and clinical oncologyFree full text
  80. Analyzing the associations between tertiary lymphoid structures and postoperative prognosis, along with immunotherapy response in gastric cancer: findings from pooled cohort studies.2024Journal of cancer research and clinical oncologyFree full text
  81. The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling.2024Journal of experimental & clinical cancer research : CRFree full text
  82. Advanced Gastric Cancer: CT Radiomics Prediction of Lymph Modes Metastasis After Neoadjuvant Chemotherapy.2024Journal of imaging informatics in medicineFree full text
  83. Implications of PD-L1 expression on the immune microenvironment in HER2-positive gastric cancer.2024Molecular cancerFree full text
  84. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial.2024Nature medicineRCT
  85. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.2024Nature medicine
  86. Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data.2024Signal transduction and targeted therapyFree full text
  87. Long-term outcomes of laparoscopic versus open distal gastrectomy for patients with advanced gastric cancer in North China: a multicenter randomized controlled trial.2024Surgical endoscopyRCTFree full text
  88. Risk factors and clinical significance of lower perigastric lymph node metastases in Siewert type II and III esophagogastric junction adenocarcinoma: a retrospective cohort study.2024Surgical endoscopyFree full text
  89. Safety and short-term outcomes of a modified valvuloplastic esophagogastrostomy versus gastric tube anastomosis after laparoscopy-assisted proximal gastrectomy: a retrospective cohort study.2024Surgical endoscopyFree full text
  90. Multi-regional sequencing reveals the genetic and immune heterogeneity of non-cancerous tissues in gastric cancer.2024The Journal of pathology
  91. Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases.2024The journal of pathology. Clinical researchFree full text
  92. Targeting SALL4 by Entinostat Inhibits the Malignant Phenotype of Gastric Cancer Cells by Reducing EMT Signaling.2023Anticancer research
  93. Prognostic significance of preoperative serum tumor markers in hepatoid adenocarcinoma of stomach (HAS).2023BMC cancerFree full text
  94. Analysis of enhanced CT imaging signs and clinicopathological prognostic factors in hepatoid adenocarcinoma of stomach patients with radical surgery: a retrospective study.2023BMC medical imagingFree full text
  95. Identification of Immunogenic Cell-Death-Related Subtypes and Development of a Prognostic Signature in Gastric Cancer.2023BiomoleculesFree full text
  96. From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space.2023Cancer cell
  97. Kinase D-interacting Substrate of 220 kDa Is Overexpressed in Gastric Cancer and Associated With Local Invasion.2023Cancer genomics & proteomicsFree full text
  98. Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET-amplified gastric cancer.2023Cancer medicineFree full text
  99. Tumor regression grade combined with post-therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma2023Cancer medicineFree full text
  100. T-cells infiltration mediates the association between neutrophil/lymphocyte ratio and survival in gastric cancer.2023Cancer medicineFree full text
  101. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.2023Cancer medicineRCT
  102. Gastric cancer-associated long non-coding RNA profiling and noninvasive biomarker screening based on a high-risk population cohort.2023Cancer medicineFree full text
  103. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.2023Cancer medicineFree full text
  104. The N6-methyladenine DNA demethylase ALKBH1 promotes gastric carcinogenesis by disrupting NRF1 binding capacity.2023Cell reports
  105. Next stage of collaboration in East Asia gastric cancer treatment.2023Chinese clinical oncology
  106. Global burden prediction of gastric cancer during demographic transition from 2020 to 2040.2023Chinese medical journalFree full text
  107. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer.2023Clinical and translational medicineFree full text
  108. Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.2023European journal of cancer (Oxford, England : 1990)
  109. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection.2023European journal of nuclear medicine and molecular imaging
  110. Death receptor 5 promotes tumor progression in gastric cancer.2023FEBS open bioFree full text
  111. Time to surgery does not affect oncologic outcomes in locally advanced gastric cancer after neoadjuvant chemotherapy: a meta-analysis.2023Future oncology (London, England)
  112. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.2023International journal of cancerRCTFree full text
  113. China special issue on gastrointestinal tumors-Improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: A multicenter, noninterventional, controlled study.2023International journal of cancer
  114. Using Normalized Carcinoembryonic Antigen and Carbohydrate Antigen 19 to Predict and Monitor the Efficacy of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer.2023International journal of molecular sciencesFree full text
  115. Aspartate β-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer.2023International journal of molecular sciencesFree full text
  116. Long-term health-related quality of life in patients with gastric cancer after total or distal gastrectomy: a propensity score-matched cohort study.2023International journal of surgery (London, England)Free full text
  117. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.2023Journal for immunotherapy of cancerFree full text
  118. Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade.2023Journal for immunotherapy of cancerFree full text
  119. Discrimination of Liver Metastases of Digestive System Neuroendocrine Tumors From Neuroendocrine Carcinoma by Computed Tomography-Based Radiomics Analysis.2023Journal of computer assisted tomography
  120. Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study.2023Journal of medical geneticsFree full text
  121. Efficacy and safety of preoperative immunotherapy alone followed by surgery in the treatment of advanced gastric cancer with MSI-H/dMMR or EBV-positive.2023Journal of the Chinese Medical Association : JCMAFree full text
  122. Transcriptome profiling of patient-derived tumor xenografts suggests novel extracellular matrix-related signatures for gastric cancer prognosis prediction.2023Journal of translational medicineFree full text
  123. Metabolite Alterations and Interactions with Microbiota in Helicobacter pylori-Associated Gastric Lesions.2023Microbiology spectrumFree full text
  124. Label-free serum proteomics for the identification of the putative biomarkers of postoperative pain in patients with gastric cancer.2023Molecular omics
  125. Liquid biopsy: circulating tumor DNA monitors neoadjuvant chemotherapy response and prognosis in stage II/III gastric cancer.2023Molecular oncologyFree full text
  126. Piceatannol enhances Beclin-1 activity to suppress tumor progression and its combination therapy strategy with everolimus in gastric cancer.2023Science China. Life sciences
  127. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance.2023Signal transduction and targeted therapyFree full text
  128. Allium vegetable intake associated with the risk of incident gastric cancer: a continuous follow-up study of a randomized intervention trial.2023The American journal of clinical nutritionRCT
  129. An exploration of gastric cancer with heterogeneous mismatch repair status.2023Virchows Archiv : an international journal of pathology
  130. Prognostic nomograms for gastric carcinoma after D2 + total gastrectomy to assist decision-making for postoperative treatment: based on Lasso regression.2023World journal of surgical oncologyFree full text
  131. Efficacy of chemotherapy versus surgery as initial treatment for gastric cancer with positive peritoneal cytology.2023World journal of surgical oncologyFree full text
  132. Response to the rechallenge of combination immunotherapy in a patient with late-stage gastric cancer: case report.2022Annals of palliative medicine
  133. Early Diagnosis of Anastomotic Leakage After Gastric Cancer Surgery Via Analysis of Inflammatory Factors in Abdominal Drainage.2022Annals of surgical oncology
  134. Associations of Annual Hospital and Surgeon Volume with Patient Outcomes After Gastrectomy: A Systematic Review and Meta-analysis.2022Annals of surgical oncology
  135. Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study.2022BMC cancerFree full text
  136. The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study.2022BMC cancerFree full text
  137. A potential decision-making algorithm based on endoscopic ultrasound for staging early gastric cancer: a retrospective study.2022BMC cancerFree full text
  138. A 9‑gene expression signature to predict stage development in resectable stomach adenocarcinoma.2022BMC gastroenterologyFree full text
  139. Epstein-Barr virus-associated gastric adenosquamous carcinoma with concurrent gastric carcinoma with lymphoid stroma: a case report and review of the literature.2022BMC gastroenterologyFree full text
  140. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.2022BMC medicineFree full text
  141. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.2022BMC medicineFree full text
  142. Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.2022BMC medicineFree full text
  143. Clinical Significance and Immune Infiltration Analyses of the Cuproptosis-Related Human Copper Proteome in Gastric Cancer.2022BiomoleculesFree full text
  144. Early detection of gastric cancer in China: progress and opportunities.2022Cancer biology & medicineFree full text
  145. SDCBP-AS1 destabilizes β-catenin by regulating ubiquitination and SUMOylation of hnRNP K to suppress gastric tumorigenicity and metastasis.2022Cancer communications (London, England)Free full text
  146. Urine proteomic signatures predicting the progression from premalignancy to malignant gastric cancer.2022EBioMedicineFree full text
  147. Beneficial effects of endoscopic screening on gastric cancer and optimal screening interval: a population-based study.2022Endoscopy
  148. Psychological distress and resilience in patients with gastroenteropancreatic neuroendocrine tumor.2022Frontiers in endocrinologyFree full text
  149. The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  150. miRNAs derived from plasma small extracellular vesicles predict organo-tropic metastasis of gastric cancer.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  151. JAK-STAT1 Signaling Pathway Is an Early Response to Helicobacter pylori Infection and Contributes to Immune Escape and Gastric Carcinogenesis.2022International journal of molecular sciencesFree full text
  152. Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis.2022Journal for immunotherapy of cancerFree full text
  153. Efficacy and predictive biomarkers of immunotherapy in Epstein-Barr virus-associated gastric cancer.2022Journal for immunotherapy of cancerFree full text
  154. Successful treatment of a case with synchronous follicular lymphoma and gastric adenocarcinoma with CD19 CAR T cells and literature review.2022Journal of clinical pharmacy and therapeutics
  155. Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer.2022Journal of extracellular vesiclesFree full text
  156. Interpretable tumor differentiation grade and microsatellite instability recognition in gastric cancer using deep learning.2022Laboratory investigation; a journal of technical methods and pathology
  157. Omitting nasogastric tube placement after gastrectomy does not enhance postoperative recovery: a propensity score matched analysis.2022Langenbeck's archives of surgery
  158. A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer.2022Molecular cancerFree full text
  159. Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery.2022Molecular pharmaceutics
  160. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.2022Nature communicationsFree full text
  161. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.2022Nature medicineFree full text
  162. Gamma-glutamyltransferase 7 suppresses gastric cancer by cooperating with RAB7 to induce mitophagy.2022Oncogene
  163. Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer.2022OncoimmunologyFree full text
  164. Identification of Preoperative Serum Metabolites Associated With Postoperative Opioid Consumption in Gastric Cancer Patients by Extreme Phenotype Sampling.2022Pain physician
  165. Dual roles of β-arrestin 1 in mediating cell metabolism and proliferation in gastric cancer.2022Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  166. Establishment of prognostic models for adenocarcinoma of oesophagogastric junction patients with neoadjuvant chemoradiotherapy: a real-world study.2022Radiation oncology (London, England)Free full text
  167. Modified π-shaped esophagojejunostomy in totally laparoscopic total gastrectomy: a report of 40 consecutive cases from a single center.2022The Journal of international medical researchFree full text
  168. Plasma lipids signify the progression of precancerous gastric lesions to gastric cancer: a prospective targeted lipidomics study.2022TheranosticsFree full text
  169. Feasibility of same-day discharge following endoscopic submucosal dissection for esophageal or gastric early cancer.2022World journal of gastroenterologyFree full text
  170. Short-and long-term outcomes of laparoscopic versus open gastrectomy in patients with gastric cancer: a systematic review and meta-analysis of randomized controlled trials.2022World journal of surgical oncologyFree full text
  171. Role of CT in the prediction of pathological complete response in gastric cancer after neoadjuvant chemotherapy.2021Abdominal radiology (New York)
  172. Utility of the gastric window in computed tomography for differentiation of early gastric cancer (T1 stage) from muscularis involvement (T2 stage).2021Abdominal radiology (New York)
  173. Ultrasensitive Gastric Cancer Circulating Tumor Cellular CLDN18.2 RNA Detection Based on a Molecular Beacon.2021Analytical chemistry
  174. Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.2021Annals of surgical oncologyFree full text
  175. Construction and Validation of a Risk-Scoring Model that Preoperatively Predicts Lymph Node Metastasis in Early Gastric Cancer Patients.2021Annals of surgical oncology
  176. Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer.2021Annals of surgical oncology
  177. The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer.2021Annals of surgical oncology
  178. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.2021BMC cancerFree full text
  179. DNA methylation signatures associated with prognosis of gastric cancer.2021BMC cancerFree full text
  180. Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery.2021BMC cancerRCTFree full text
  181. Combination of tumor markers predicts progression and pathological response in patients with locally advanced gastric cancer after neoadjuvant chemotherapy treatment.2021BMC gastroenterologyFree full text
  182. Development and validation of a novel staging system integrating the number and location of lymph nodes for gastric adenocarcinoma.2021British journal of cancerFree full text
  183. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.2021Cancer communications (London, England)Free full text
  184. Insulin gene enhancer protein 1 mediates glycolysis and tumorigenesis of gastric cancer through regulating glucose transporter 4.2021Cancer communications (London, England)Free full text
  185. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients.2021Cancer letters
  186. Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm.2021Cancer medicineFree full text
  187. Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities.2021Cancer medicineFree full text
  188. Double Tract Reconstruction Reduces Reflux Esophagitis and Improves Quality of Life after Radical Proximal Gastrectomy for Patients with Upper Gastric or Esophagogastric Adenocarcinoma.2021Cancer research and treatmentFree full text
  189. An Innovative Prognostic Model Based on Four Genes in Asian Patient with Gastric Cancer.2021Cancer research and treatmentFree full text
  190. EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer.2021Cell proliferationFree full text
  191. Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis.2021Chinese medical journalFree full text
  192. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.2021Clinical cancer research : an official journal of the American Association for Cancer Research
  193. Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.2021Diagnostic pathologyFree full text
  194. Effect of administration of a proton pump inhibitor for ulcerative differentiated early gastric cancer prior to endoscopic submucosal dissection.2021Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  195. Proteomic profiling identifies signatures associated with progression of precancerous gastric lesions and risk of early gastric cancer.2021EBioMedicineFree full text
  196. Impact of 68Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring.2021European journal of nuclear medicine and molecular imaging
  197. Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?2021European journal of radiology
  198. Comparison of totally laparoscopic and laparoscopic assisted gastrectomy after neoadjuvant chemotherapy in locally advanced gastric cancer.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  199. Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  200. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  201. Deep learning system for lymph node quantification and metastatic cancer identification from whole-slide pathology images.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  202. ASB16-AS1 up-regulated and phosphorylated TRIM37 to activate NF-κB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  203. Profiling heterogenous sizes of circulating tumor microemboli to track therapeutic resistance and prognosis in advanced gastric cancer.2021Human cellFree full text
  204. CXCL16 Promotes Gastric Cancer Tumorigenesis via ADAM10-Dependent CXCL16/CXCR6 Axis and Activates Akt and MAPK Signaling Pathways.2021International journal of biological sciencesFree full text
  205. MicroRNA-135b/CAMK2D Axis Contribute to Malignant Progression of Gastric Cancer through EMT Process Remodeling.2021International journal of biological sciencesFree full text
  206. Identification and Validation of Plasma Metabolomic Signatures in Precancerous Gastric Lesions That Progress to Cancer.2021JAMA network openFree full text
  207. Effects of laparoscopic-assisted gastrectomy on elderly patients with gastric cancer.2021Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  208. Surgical and oncological efficacy of laparoscopic-assisted total gastrectomy versus open total gastrectomy for gastric cancer by propensity score matching: a retrospective comparative study.2021Journal of cancer research and clinical oncologyFree full text
  209. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial.2021Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCTFree full text
  210. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.2021Journal of hematology & oncologyFree full text
  211. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.2021Journal of molecular medicine (Berlin, Germany)
  212. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.2021Journal of surgical oncology
  213. Short-term outcomes after totally laparoscopic total gastrectomy with esophagojejunostomy constructed by π-shaped method versus overlap method.2021Journal of surgical oncology
  214. Comparison of the short-term outcomes of laparoscopic and open total or proximal gastrectomy using the transorally inserted anvil (OrVilTM) for the proximal reconstruction: a propensity score matching analysis.2021Langenbeck's archives of surgery
  215. Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications.2021Molecular cancerFree full text
  216. Association of serotonin transporter-linked polymorphic region (5-HTTLPR) with heat pain stimulation and postoperative pain in gastric cancer patients.2021Molecular painFree full text
  217. Genomic and transcriptomic profiling of hepatoid adenocarcinoma of the stomach.2021Oncogene
  218. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.2021Oncogene
  219. Proteomics provides individualized options of precision medicine for patients with gastric cancer.2021Science China. Life sciences
  220. Risk factors for esophagojejunal anastomotic leakage after curative total gastrectomy combined with D2 lymph node dissection for gastric cancer.2021The Journal of international medical researchFree full text
  221. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-2021The Lancet. OncologyRCT
  222. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 t2021The lancet. Gastroenterology & hepatologyRCT
  223. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).2021The oncologistFree full text
Chinese-language papers (not in the count)20
  1. [Development and dissemination of precision medicine approaches in gastric cancer management].2025Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciencesFree full text
  2. [Development status and prospects of functional preservation surgery for gastric cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Precise diagnosis and treatment strategies for gastric cancer guided by clinical issues].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Tissue and plasma proteomic signatures associated with the risk of gastric cancer].2025Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
  5. [Surgical management of gastric cancer in the era of immunotherapy].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  6. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction]2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Neoadjuvant immunotherapy ushers in a new era of gastric cancer treatment].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Impact and intervention of postoperative complications after gastric cancer surgery from a health economics perspective].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Regarding the selection of individualized therapy after neoadjuvant therapy for gastrointestinal tumors].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Incidence of postoperative complications in Chinese patients with gastric or colorectal cancer based on a national, multicenter, prospective, cohort study].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  11. [Quality control in the establishment and management of gastric cancer database].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  12. [Interpretation on the report of global cancer statistics 2022].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  13. [Clinicopathological characteristics of gastric SMARCA4-deficient undifferentiated/rhabdoid carcinoma].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  14. [Building world leading surgical oncology for gastric cancer in China].2023Zhonghua wai ke za zhi [Chinese journal of surgery]
  15. [Surveys on diagnosis and treatment of esophagogastric junction adenocarcinoma by the Chinese Laparoscopic Gastrointestinal Surgery Study Group-10 Research Team].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. [The risk of incident gastric cancer for populations with different precancerous gastric lesions: a prospective follow-up study].2022Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  17. [Dissection borders of laparoscopic lower mediastinal lymphadenectomy for adenocarcinoma of esophagogastric junction and the quality control].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  18. [Accurate diagnosis and individualized treatment of advanced gastric cancer: pathological detection of biomarkers based on cancer tissue samples].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  19. [Progress in gastric cancer with positive peritoneal cytology].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  20. [Implementation strategy of enhanced recovery after surgery in perioperative management of gastric cancer].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status147
  1. Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI CancersNot yet recruitingNCT07656740Lead sponsorStart 2026-06
  2. Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric CancerRecruitingNCT06306755Lead sponsorN/AStart 2024-06
  3. Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric AdenocarcinomaRecruitingNCT04047953Lead sponsorN/AStart 2019-09
  4. Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric AdenocarcinomaStatus unknownNCT05816863Lead sponsorStart 2023-03
  5. Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsStatus unknownNCT04764084Lead sponsorPhase 1Start 2021-04
  6. Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for AGCStatus unknownNCT03708783Lead sponsorN/AStart 2018-07
  7. Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant ChemotherapyStatus unknownNCT04408859Lead sponsorStart 2018-04
  8. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Lead sponsorPhase 3Start 2017-04
  9. Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric CancerCompletedNCT03425058Lead sponsorStart 2017-11
  10. Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric CancerStatus unknownNCT02464215Lead sponsorN/AStart 2014-03
  11. DNA Methylation Biomarkers and Metastasis of Gastric CarcinomaCompletedNCT02159339Lead sponsorStart 2012-12
  12. Xeloda Plus Paclitaxel in Gastric Cancer With Liver MetastasisStatus unknownNCT01167049Lead sponsorPhase 2Start 2009-08
  13. ctDNA-MRD Monitoring After Resection in Gastric CancerRecruitingNCT06893133Lead (inferred)Start 2025-04
  14. Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric CancerRecruitingNCT07127822Lead (inferred)Phase 2Start 2025-12
  15. NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid TumorRecruitingNCT06134960Lead (inferred)Phase 1Start 2024-11
  16. Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon CancersRecruitingNCT06580574Lead (inferred)Phase 2Start 2024-09
  17. Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target VisualizationRecruitingNCT06429891Lead (inferred)N/AStart 2024-08
  18. Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GCRecruitingNCT06023758Lead (inferred)Phase 2Start 2023-09
  19. Perioperative Cadonilimab (AK104) in Locally Advanced MSI-H/dMMR Gastric or Gastroesophageal Junction and Colorectal AdenocarcinomaActive, not recruitingNCT04556253Lead (inferred)Phase 2Start 2024-02
  20. Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJAStatus unknownNCT06222944Lead (inferred)Phase 2Start 2024-02
  21. The Effect of MDT Plus SDM on Survival Benefit of Advanced Gastric CancerStatus unknownNCT06432205Lead (inferred)Start 2023-11
  22. Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard TherapyStatus unknownNCT05649163Lead (inferred)Start 2023-01
  23. Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid TumorsStatus unknownNCT05393986Lead (inferred)Phase 1Start 2022-08
  24. Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring SystemStatus unknownNCT05165602Lead (inferred)Start 2022-01
  25. Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric CancerStatus unknownNCT05227378Lead (inferred)N/AStart 2022-03
  26. Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers.Status unknownNCT05593419Lead (inferred)Start 2022-10
  27. Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal CancerStatus unknownNCT04777162Lead (inferred)Phase 2Start 2021-03
  28. Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the StomachWithdrawnNCT04863430Lead (inferred)Phase 2Start 2021-05
  29. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsStatus unknownNCT04584008Lead (inferred)N/AStart 2020-09
  30. Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction AdenocarcinomaStatus unknownNCT04609176Lead (inferred)Phase 2Start 2020-11
  31. Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Esophagogastric Junction CancerStatus unknownNCT04443478Lead (inferred)Start 2020-08
  32. Study on the Effectiveness of Gastroscope Operation Quality Control Based on Artificial Intelligence TechnologyCompletedNCT04384575Lead (inferred)Start 2020-02
  33. Function Preserving Gastrectomy for T1/2 Gastric Cancer PatientsStatus unknownNCT03874871Lead (inferred)Start 2019-03
  34. Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric CancerStatus unknownNCT04202601Lead (inferred)Phase 1/Phase 2Start 2019-12
  35. Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric CancerStatus unknownNCT05348161Lead (inferred)N/AStart 2019-01
  36. Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision MakingStatus unknownNCT03413514Lead (inferred)N/AStart 2018-01
  37. Verifying the Specificity of a New Method in Predicting Lymph Node Metastasis in Early Gastric Cancer PatientsStatus unknownNCT03632746Lead (inferred)Start 2018-09
  38. Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric CancerStatus unknownNCT03480256Lead (inferred)Phase 1Start 2018-07
  39. Laparoscopic Versus Open Gastrectomy for Elderly Local Advanced Gastric Cancer PatientsStatus unknownNCT03564834Lead (inferred)Phase 2Start 2018-08
  40. Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric CancerStatus unknownNCT03575637Lead (inferred)Phase 2Start 2018-07
  41. Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid BiopsyStatus unknownNCT04993378Lead (inferred)Start 2018-11
  42. The Origin of Infrapyloric ArteryCompletedNCT03071237Lead (inferred)Start 2017-03
  43. MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal CancerStatus unknownNCT03400657Lead (inferred)Start 2017-11
  44. Treatment Strategy for Stage IV Gastric Cancer with Positive Peritoneal Cytology As the Only Non-curable FactorTerminatedNCT02969122Lead (inferred)N/AStart 2016-11
  45. Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric CancerStatus unknownNCT02610218Lead (inferred)Start 2016-04
  46. The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative TreatmentsStatus unknownNCT03493880Lead (inferred)Start 2015-09
  47. Octreotide LAR as Maintenance Treatment for Patients With NECStatus unknownNCT02409849Lead (inferred)Phase 2Start 2015-04
  48. A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant ChemotherapyStatus unknownNCT02404753Lead (inferred)Phase 2Start 2015-04
  49. Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric CancerStatus unknownNCT02375997Lead (inferred)Phase 3Start 2014-10
  50. Study on Neoadjuvant Chemotherapy for Advanced Gastric CancerStatus unknownNCT02163291Lead (inferred)Phase 2Start 2013-12
  51. Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric CancerCompletedNCT01625702Lead (inferred)N/AStart 2012-06
  52. A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 SurgeryStatus unknownNCT01679340Lead (inferred)Phase 2Start 2011-04
  53. Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum MetastasisStatus unknownNCT01471132Lead (inferred)Phase 2Start 2011-09
  54. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  55. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  56. A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line TreatmentRecruitingNCT07518147Study sitePhase 3Start 2026-05
  57. A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07315750Study sitePhase 3Start 2026-01
  58. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)RecruitingNCT07221149Study sitePhase 2/Phase 3Start 2026-03
  59. A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid TumorsRecruitingNCT07354711Study sitePhase 1/Phase 2Start 2026-01
  60. LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction AdenocarcinomaRecruitingNCT07362186Study sitePhase 3Start 2026-04
  61. Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction CancerRecruitingNCT07522151Study sitePhase 3Start 2026-05
  62. Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingNCT07700979Study sitePhase 3Start 2026-09
  63. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  64. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  65. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06760819Study sitePhase 2Start 2025-02
  66. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  67. A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06944496Study sitePhase 3Start 2025-05
  68. To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid TumorsRecruitingNCT07594964Study sitePhase 1Start 2025-08
  69. An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid TumorsRecruitingNCT07371663Study sitePhase 1/Phase 2Start 2025-12
  70. A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ AdenocarcinomaRecruitingNCT07023315Study sitePhase 3Start 2025-08
  71. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  72. BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06773312Study sitePhase 1Start 2025-02
  73. A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR PathwayNot yet recruitingNCT06614751Study sitePhase 1Start 2024-11
  74. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  75. A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)RecruitingNCT07547787Study siteStart 2024-12
  76. DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line TherapyRecruitingNCT06221748Study sitePhase 2/Phase 3Start 2024-02
  77. Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingNCT06469944Study sitePhase 1/Phase 2Start 2024-09
  78. Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT06155383Study sitePhase 2Start 2023-11
  79. M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.RecruitingNCT06177041Study sitePhase 3Start 2023-12
  80. AI Prediction of Gastric Cancer Response to Neoadjuvant ChemotherapyRecruitingNCT06035250Study siteStart 2023-09
  81. Prediction of Peritoneal Metastasis for Gastric Cancer Based on RadiomicsRecruitingNCT05722275Study siteStart 2023-01
  82. A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal TumorsRecruitingNCT06008054Study sitePhase 2Start 2023-11
  83. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorRecruitingNCT05262491Study sitePhase 1Start 2022-02
  84. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  85. A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Study sitePhase 1Start 2022-10
  86. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid TumorsRecruitingNCT04900818Study sitePhase 1Start 2021-06
  87. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  88. A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or AmplificationTerminatedNCT06585488Study sitePhase 1Start 2024-12
  89. A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.Active, not recruitingNCT06116136Study sitePhase 1/Phase 2Start 2024-08
  90. A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Study sitePhase 1Start 2024-03
  91. A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in ChinaCompletedNCT06585501Study siteStart 2024-08
  92. A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric CancerActive, not recruitingNCT05980481Study sitePhase 2/Phase 3Start 2023-08
  93. ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Active, not recruitingNCT05632939Study sitePhase 1/Phase 2Start 2023-02
  94. Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric CancerStatus unknownNCT06008925Study sitePhase 1/Phase 2Start 2022-11
  95. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  96. To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Study sitePhase 1/Phase 2Start 2022-04
  97. Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1CompletedNCT05383482Study sitePhase 1/Phase 2Start 2022-07
  98. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric CancerTerminatedNCT05149807Study sitePhase 2/Phase 3Start 2022-01
  99. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  100. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  101. A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal CancerActive, not recruitingNCT04950322Study sitePhase 3Start 2021-12
  102. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  103. A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionCompletedNCT04661150Study sitePhase 2Start 2021-03
  104. A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)TerminatedNCT04933227Study sitePhase 2Start 2021-08
  105. Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)Active, not recruitingNCT04704934Study sitePhase 3Start 2021-05
  106. Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric CancerActive, not recruitingNCT04725994Study sitePhase 1/Phase 2Start 2021-06
  107. Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid TumorStatus unknownNCT05009966Study sitePhase 1Start 2021-09
  108. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  109. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR AlterationsStatus unknownNCT05019794Study sitePhase 2Start 2020-05
  110. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Study sitePhase 3Start 2020-07
  111. Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without TislelizumabCompletedNCT04276493Study sitePhase 1/Phase 2Start 2020-03
  112. Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal MetastasisStatus unknownNCT04222114Study sitePhase 3Start 2020-10
  113. Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid TumorsCompletedNCT04400383Study sitePhase 1Start 2020-06
  114. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  115. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell InjectionActive, not recruitingNCT04581473Study sitePhase 1/Phase 2Start 2020-10
  116. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  117. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  118. A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaCompletedNCT03852251Study sitePhase 1/Phase 2Start 2019-01
  119. A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic TherapyCompletedNCT03813784Study sitePhase 3Start 2019-03
  120. A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerStatus unknownNCT04139135Study sitePhase 3Start 2019-12
  121. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  122. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  123. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  124. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  125. A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerCompletedNCT03472365Study sitePhase 2Start 2018-04
  126. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2CompletedNCT03556345Study sitePhase 2Start 2018-07
  127. Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Study sitePhase 3Start 2018-10
  128. A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild TumorStatus unknownNCT03393416Study sitePhase 1Start 2018-04
  129. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Study sitePhase 2Start 2018-07
  130. Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal TumorsStatus unknownNCT03507998Study sitePhase 1Start 2017-06
  131. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  132. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  133. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  134. Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)TerminatedNCT03019588Study sitePhase 3Start 2017-02
  135. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)CompletedNCT03221426Study sitePhase 3Start 2017-10
  136. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  137. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownNCT03023436Study sitePhase 3Start 2016-01
  138. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  139. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  140. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma SurgeryStatus unknownNCT02130752Study siteN/AStart 2014-10
  141. Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric CancerStatus unknownNCT02378389Study sitePhase 1Start 2014-09
  142. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  143. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  144. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  145. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09
  146. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09
  147. Study of S-1, S-1/CDDP, and 5-FU/CDDP for Advanced Gastric CancerCompletedNCT00202969Study sitePhase 3Start 2005-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 002025

48 hospitals in Beijing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology
Papers it led4
  1. Knockdown of PRDX2 Inhibits the Proliferation, Growth, Migration, Invasion, and MMP9 Activity of Ewing's Sarcoma Cells Cultured In Vitro.2024Cancer reports (Hoboken, N.J.)
  2. Regulatory role of PI3K/Akt/WNK1 signal pathway in mouse model of bone cancer pain.2023Scientific reports
  3. SNHG9/miR-214-5p/SOX4 feedback loop regulates osteosarcoma progression.2022Neoplasma
  4. Primary EWS/PNET of the lung with TP53 germline and SKT11 somatic mutation: A case report and review of the literature.2022Thoracic cancer
Earlier papers (2016–2020)6
  1. KIF18B promotes tumor progression in osteosarcoma by activating β-catenin.2020Cancer biology & medicine
  2. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.2020International journal of clinical oncology
  3. Construction of Anti-hPD-L1 HCAb Nb6 and in Situ 124I Labeling for Noninvasive Detection of PD-L1 Expression in Human Bone Sarcoma.2019Bioconjugate chemistry
  4. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.2019Molecular carcinogenesis
  5. Association between interleukin 8 -251 A/T and +781 C/T polymorphisms and osteosarcoma risk in Chinese population: a case-control study.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  6. [Deficiencies in the Diagnosis and Treatment of Pulmonary Metastatic Osteosarcoma: A Chinese Multidisciplinary Survey].2016Zhongguo fei ai za zhi = Chinese journal of lung cancer
All its trials on ClinicalTrials.gov, any status1
  1. TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid TumorsTerminatedNCT06438783Study sitePhase 1Start 2024-02

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 12 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 2.3%.

Papers led
12
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 4420232024: 5520242025: 112025

23 hospitals in Beijing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07559864

    Age 18 years to Not stated (registered criteria)

    Led by Peking University Cancer HospitalBeijing

  2. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)
Papers it led12
  1. Long-term outcomes of ripretinib versus sunitinib in Chinese patients with advanced gastrointestinal stromal tumor: An updated analysis of a phase 2 randomized clinical trial.2025CancerRCT
  2. Clinical Benefit of Avapritinib in KIT-Mutant Gastrointestinal Stromal Tumors: A Post Hoc Analysis of the Phase I NAVIGATOR and Phase I/II CS3007-001 Studies.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  3. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China.2024European journal of cancer (Oxford, England : 1990)RCT
  4. CT features combined with RECIST 1.1 criteria improve progression assessments of sunitinib-treated gastrointestinal stromal tumors.2024European radiology
  5. Percutaneous ultrasound-guided radiofrequency ablation for patients with liver metastases from gastrointestinal stromal tumors.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  6. An additional gastrojejunostomy may reduce the incidence of moderate and severe delayed gastric emptying after distal segmental duodenectomy for gastrointestinal stromal tumors.2024World journal of surgical oncology
  7. Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China.2023Advances in therapy
  8. Cytoreductive surgery offers prognostic benefits in metastatic gastrointestinal stromal tumors with generalized progression following imatinib therapy: a single institute retrospective study.2023BMC surgery
  9. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.2023The oncologist
  10. Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.2023The oncologist
  11. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.2022Clinical cancer research : an official journal of the American Association for Cancer Research
  12. Could computed tomography be used as a surrogate of endoscopic ultrasonography in the screening and surveillance of small gastric Gastrointestinal stromal tumors?2021European journal of radiology
Earlier papers (2016–2020)16
  1. The current status of and prospects in research regarding gastrointestinal stromal tumors in China.2020Cancer
  2. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.2020Cancer medicine
  3. Heterogeneity of metastatic gastrointestinal stromal tumor on texture analysis: DWI texture as potential biomarker of overall survival.2020European journal of radiology
  4. [Current status and progress in novel drug research for gastrointestinal stromal tumors].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. Cytoreductive surgery for metastatic gastrointestinal stromal tumors followed by sunitinib compared to followed by imatinib-a multi-center cohort study.2019European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  6. [Advances in radiological studies of gastrointestinal stromal tumors].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [To improve the understanding of CD117-negative gastrointestinal stromal tumor].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. MRI in predicting the response of gastrointestinal stromal tumor to targeted therapy: a patient-based multi-parameter study.2018BMC cancer
  9. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.2018Future oncology (London, England)
  10. Non-Gaussian diffusion imaging with a fractional order calculus model to predict response of gastrointestinal stromal tumor to second-line sunitinib therapy.2018Magnetic resonance in medicine
  11. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.2018World journal of gastroenterology
  12. [Analysis of biological characteristics and prognosis on gastrointestinal stromal tumor with PDGFRA gene mutation].2018Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes.2017Future oncology (London, England)
  14. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors.2016Oncotarget
  15. [Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  16. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status15
  1. A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTStatus unknownNCT02776878Lead sponsorN/AStart 2016-05
  2. Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingNCT07559864Lead (inferred)Phase 2Start 2025-07
  3. A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard TreatmentNot yet recruitingNCT06772233Lead (inferred)Phase 2Start 2025-07
  4. Ripretinib in Chinese Patients With Advanced GIST: a Real World StudyStatus unknownNCT05697107Lead (inferred)Start 2021-05
  5. Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular CharacteristicsStatus unknownNCT04584008Lead (inferred)N/AStart 2020-09
  6. Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter TrialStatus unknownNCT04106024Lead (inferred)Phase 2Start 2018-10
  7. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  8. Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real WorldCompletedNCT05381753Study siteStart 2022-08
  9. A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Active, not recruitingNCT05245968Study sitePhase 1Start 2021-12
  10. Clinical Evaluation of Genetron D842V PCR Kit in GIST PatientsCompletedNCT05400018Study siteStart 2020-11
  11. A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)CompletedNCT04282980Study sitePhase 2Start 2020-04
  12. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  13. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  14. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03
  15. Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal TumorCompletedNCT00793871Study sitePhase 4Start 2008-11

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

24 hospitals in Beijing for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

17 hospitals in Beijing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

15 hospitals in Beijing for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplant

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led no English-language PubMed papers on anti-NMDA receptor encephalitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Beijing for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

北京大学肿瘤医院

Peking University Cancer Hospital

北京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Peking University Cancer Hospital & Institute; Peking University Cancer Hospital and Institute; Beijing Cancer Hospital and Institute; Beijing Cancer Hospital; Peking University Cancer Hospital Yunnan; Beijing Cancer Hospital & Institute; Peking University Cancer Hospital/Institute; Peking University Cancer Hospital &Institute

Suggest a correctionDownload the data